November Monthly Price Drop: ₹80,000 all-inclusive until 16 November, 11:59 PM IST. 52% off.|Foresight ₹1,40,000 ₹67,797 + 18% GST|12 months of accessGet Foresight
All board jobs

Applications closed

This seat is no longer taking applications — closed on 14 September 2026.

The brief stays here for reference. Seats like it open every week.

See live board seats
India ID ExchangeWoman Independent Director Woman Independent Director Mandate

Woman Independent Director — Contract Research Organisation | Quality & Global Clients

Confidential company Pune· Contract Research Organisation
Audit

Closed 14 September 2026

Reference: GILA/ID/WID-020/CRO
Board seat: Independent Director, Non-Executive
Primary board location: Pune with laboratories in western and southern India
Meeting model: Five board, quarterly quality/risk and two laboratory visits
Mandate type: Woman Independent Director Mandate
Status: Confidential live-search specification; client identity released only after conflict clearance and NDA.

The anonymised enterprise

A listed contract research organisation providing bioanalytical, toxicology and early-development services to global pharmaceutical and biotechnology sponsors. It is not a hospital or single-specialty care provider.

Revenue is ₹1,000–1,600 crore, mostly foreign currency. The company is expanding regulated-study capacity and wants functional diversity in scientific quality, data integrity and client concentration.

The board problem and strategic reason for appointment

The strategic issue is whether growth can outpace the supply of qualified investigators and quality systems. A data-integrity failure, inspection observation or loss of one global sponsor can destroy value faster than a weak quarter.

The board is not buying a credential. It is appointing an independent decision-maker who can convert this problem into a governed sequence of choices, evidence and accountability. Success will be judged by the quality of decisions and control improvement, not by the number of recommendations made.

Board position, authority and interfaces

Chair of Quality & Risk; Audit member for revenue, foreign exchange and capitalisation; direct access to Quality Assurance independent of operations.

The appointee will have direct, unfiltered access to the Company Secretary and to the relevant control-function leaders. Any advisory support requested by the board must remain management-executed: the director sets questions, tolerances and evidence standards, but does not become an executive or consultant.

First 12–18 month strategic charter

  1. Define board tolerances for data-integrity, protocol deviation and inspection readiness; review quality-unit independence, investigator workload and CAPA recurrence; challenge client concentration and master-service-agreement termination economics; govern laboratory-capacity capex using utilisation, validation and qualified-person readiness gates
  2. Enter as a full board contributor with a defined committee and strategic charter; the appointment will not be framed or evaluated as a numerical diversity exercise.
  3. Improve the quality of debate by testing whose evidence reaches the board, which stakeholder voices are absent, and whether succession and culture data reveal hidden concentration or conduct risk.

Decision profile sought

Essential evidence

  • Woman scientist, life-sciences quality leader, CRO/pharma executive or regulated-laboratory operator; board-level judgement; global inspection exposure

Differentiators

  • US FDA, EMA or OECD GLP inspection leadership; experience protecting quality-unit independence during rapid growth

GILA will assess functional authority first, sector relevance second, genuine independence and the confidence to resist being cast as the board member responsible for every people or diversity matter. Candidates should expect a case discussion based on an ambiguous board decision from this mandate, not a career-history interview alone.

Independence, suitability and downside diligence

The search will apply Section 149(6), Sections 164–165, Schedule IV and the applicable listing or sector rules to the entity’s legally verified status at the appointment date. Databank/proficiency status, listed-entity directorship and committee ceilings, pecuniary relationships, relatives’ interests, recent audit/advisory work and interlocking directorships will be checked. The appointment is subject to formal legal and secretarial confirmation; this posting is not a substitute for that determination.

Mandate-specific screens: Current sponsor, competitor CRO or laboratory-vendor relationships; authorship/consulting conflicts on active studies; any executive involvement in quality decisions after appointment.

Before accepting the seat, the candidate will receive under NDA the latest board composition, committee charters, material litigation/regulatory schedule, related-party map, last audited accounts, current D&O policy and the specific risk papers necessary to make an informed liability assessment.

Twelve-month outcomes

The board expects a capability-led appointment whose contribution is measurable in strategy, risk and committee performance—not only composition statistics. For this particular seat, the evidence will be:

  • Recurring CAPA and protocol deviations trend downward with verified effectiveness; capacity released only after validation and staffing gates; top-client downside plan approved

Commitment, protection and economics

  • Expected load: 20–25 days annually plus inspection availability.
  • Terms: Five-year term; committee-chair fee; product/professional and D&O coverage with regulatory investigation costs.
  • Protection: Appointment letter, deed of indemnity where legally available, appropriate D&O cover including discovery/run-off terms, access to independent advice under the board-approved protocol, and complete minuting of dissent.
  • Equity: No stock options where the appointment is legally an independent-director seat subject to Section 149(9). Any private-company structure outside that perimeter will be expressly classified and separately advised; no equity is implied by this posting.

Search process

Conflict pre-clearance → GILA/SYMPHONY™ board-fit interview → mandate case → document-led diligence under NDA → references from board peers and control functions → NRC/owner interviews → statutory, regulatory and reputation checks → board recommendation. Candidate consent, disclosures and appointment approvals will follow the law and the entity’s constitutional documents.

New to Pharma & Healthcare boards?

What these boards look for, how the committees are composed, what the seats pay, and the eligibility rules that apply.

Seats like this, open now

India ID ExchangeMedium Term

Audit Committee Chair — Digital Trust, Revenue Integrity and Platform Resilience

Confidential listed technology and trust-services company Mumbai· Technology and Digital Services
Current Listing Foresight Priority PeriodAudit Committee Chair & Financial Expert First-timer eligibilityForesight shows whether this board will consider a first-time independent director, before you spend an application.Click to get Foresight →AuditNRCCSR

The business delivers technology and trust-sensitive services. Its financial result depends on contracts, platform availability, protected information, customer acceptance and continuing service obligations. The Audit Committee Chair must therefore examine not only whether the…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 43d 17:38:58· 29 December 2026 at 11:59 pm IST
Posted 30 OctApply
India ID ExchangeMedium Term

NRC Chair and Risk Member — Listed Specialist Finance Institution

Confidential listed specialist finance institution Delhi NCR· Banking and Financial Services
Current Listing Foresight Priority PeriodSector-Regulated Independent DirectorNRCRiskStakeholders

The independent director will chair NRC and serve on Risk, Stakeholders Relationship and CSR. The mandate is to ensure that leadership, incentives and succession can withstand the institution's aggregate risk before individual businesses use their own metrics to explain it away.…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 42d 17:38:58· 28 December 2026 at 11:59 pm IST
Posted 30 OctApply
India ID ExchangeMedium Term

NRC Chair — Process Manufacturing, Succession and Long-Horizon Capability

Confidential listed process-manufacturing company Noida· Process Manufacturing
Current Listing Foresight Priority PeriodNRC Chair & Board SuccessionNRC

The company combines process engineering, manufacturing, resource stewardship, supply networks and customer relationships that mature over long cycles. The NRC Chair must ensure that leadership succession and reward preserve capability across cycles rather than optimise only the…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 41d 17:38:58· 27 December 2026 at 11:59 pm IST
Posted 29 OctApply
India ID ExchangeMedium Term

NRC Chair and Risk Member — Financial Markets Leadership and Conduct

Confidential listed financial-services company Mumbai· Banking and Financial Services
Current Listing Foresight Priority PeriodNRC Chair & Board SuccessionNRCRiskAudit

The seat chairs NRC and participates in Risk and Audit. The Board needs a director who can judge whether leadership, incentives and control-function stature support fiduciary conduct through changing markets. In financial services, stakeholder confidence can alter flows,…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 39d 17:38:58· 25 December 2026 at 11:59 pm IST
Posted 28 OctApply